Key result
This paper is a study protocol for a randomized controlled trial evaluating losartan in euvolemic hemodialysis patients, and therefore contains no clinical results.
Why the study?
Does losartan improve blood pressure control (systolic BP < 140 mm Hg) in postdialysis euvolemic hypertensive patients compared to non-RAAS-inhibitor therapy?
RCT (n=88)
Single-blind
Covariate Adaptive Randomization
No
Does losartan improve blood pressure control (systolic BP < 140 mm Hg) in postdialysis euvolemic hypertensive patients compared to non-RAAS-inhibitor therapy?
Answers are grounded in this paper and cite their sources.
This study protocol outlines a randomized trial to evaluate the efficacy of losartan for blood pressure control in euvolemic hemodialysis patients.
INTRODUCTION: Volume overload and the renin-aldosterone-angiotensin system (RAAS) are 2 major factors contributing to hypertension (HTN) among hemodialysis (HD) patients. Although volume-dependent components of HTN can be corrected by appropriate volume removal, a proportion of HD patients experience elevated blood pressure (BP) despite achieving euvolemic and ideal dry weight. METHOD AND ANALYSIS: A single center, prospective, randomized, parallel design, single-blind trial will be conducted in the Malaysian state of Kelantan among postdialysis euvolemic hypertensive patients that are on regular dialysis at least 3 times a week. The primary outcome of the trial will be to note the effectiveness of losartan (RAAS inhibitor) in reducing systolic BP < 140 mm Hg compared to standard non-RAAS-inhibitor antihypertensive therapy. The secondary outcome will be to look at all causes of mortality. A body composition monitor (BCM) will be used to assess postdialysis volume and dry weight. Postdialysis euvolemic patients that have systolic BP > 140 mm Hg will be randomized using Covariate Adaptive Randomization to standard or treatment arm. Participants in the treatment arm will be given 50 mg of losartan once daily except on dialysis days, whereas the standard arm patients will be prescribed non-RAAS antihypertensive agents. The study participants will be followed for a period of 12 months. A Wilcoxon statistical test will be performed to note the difference in BP from baseline up to 12 months using Statistical Package for the Social Sciences (SPSS) 20. ETHICAL AND TRIAL REGISTRATION: The study protocols are approved from the Ethical and Research Committee of the Universiti Sains Malaysia (USM/JEPeM/15050173). The trial is registered under the Australia New Zealand Clinical Trial Registry (ACTRN12615001322527). The trial was registered on 2/12/2015 and the 1st patient was enrolled on 10/12/2015. The trial was formally initiated on 16/02/2016. CONCLUSION: Management of HTN among HD patients requires understanding the primary cause of HTN and treating accordingly. The current trial is an attempt to reduce BP among postdialysis euvolemic but hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Aftab et al. (2017) conducted an RCT in Hypertension in euvolemic hemodialysis patients (n=88). Losartan vs. Standard non-RAAS-inhibitor antihypertensive therapy was evaluated on Postdialysis BP of <140/90 mm Hg maintained for 4 weeks. This paper is a study protocol for a randomized controlled trial evaluating losartan in euvolemic hemodialysis patients, and therefore contains no clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: